Student Research Group, Endocrinology Section at the Department of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, 60-355 Poznan, Poland.
Department of General and Transplant Surgery, Poznan University of Medical Sciences, 60-352 Poznan, Poland.
Int J Mol Sci. 2024 Nov 14;25(22):12221. doi: 10.3390/ijms252212221.
Metabolic syndrome (MS) comprises several symptoms or disorders that significantly increase the risk of developing atherosclerosis and type 2 diabetes. This study aims to determine the direct impact of testosterone therapy on the components of MS; although excluding type 2 diabetes cases. The authors conducted a systematic literature search of PubMed, Scopus, and Cochrane databases without date limits, using keywords such as "testosterone therapy", "metabolic syndrome" and "men". The studies included in our review focused on the effects of testosterone replacement therapy (TRT) in male patients with MS, yet rejecting individuals where type 2 diabetes constituted the only diagnosis. A meta-analysis was performed using PQStat v1.8.6 software. The overall effect size (mean difference) was calculated using a random effects model. Our meta-analysis indicates that testosterone therapy leads to improvement in the components of MS. Significant reductions were observed in waist circumference (WC) (95% CI: -0.709 to 0.094; = 0.011), as well as in triglycerides (TG) (95% CI: -0.474 to 0.120; = 0.039). These findings support the potential therapeutic benefits of testosterone treatment in managing MS. However, further research is vital to explore the long-term effects and the safety of this therapy in patients with metabolic syndrome.
代谢综合征（MS）包括几种症状或疾病，这些症状或疾病会显著增加动脉粥样硬化和 2 型糖尿病的风险。本研究旨在确定睾丸激素治疗对 MS 成分的直接影响；尽管排除了 2 型糖尿病病例。作者对 PubMed、Scopus 和 Cochrane 数据库进行了系统的文献检索，没有时间限制，使用了“睾丸激素治疗”、“代谢综合征”和“男性”等关键词。我们综述中纳入的研究侧重于睾丸激素替代疗法（TRT）对 MS 男性患者的影响，但拒绝仅患有 2 型糖尿病的个体。使用 PQStat v1.8.6 软件进行了荟萃分析。使用随机效应模型计算总体效应大小（均数差）。我们的荟萃分析表明，睾丸激素治疗可改善 MS 的成分。腰围（WC）（95%CI：-0.709 至 0.094；=0.011）和甘油三酯（TG）（95%CI：-0.474 至 0.120；=0.039）显著降低。这些发现支持睾丸激素治疗在管理 MS 方面的潜在治疗益处。然而，进一步的研究对于探索这种治疗方法在代谢综合征患者中的长期效果和安全性至关重要。
